{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:39:41Z","timestamp":1789465181576,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007263","name":"Astellas Foundation for Research on Metabolic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Heart Failure Society Tsuchiya Foundation"},{"DOI":"10.13039\/100005292","name":"Brigham and Women\u2019s Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Finerenone was shown to improve overall health status, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) score, in heart failure with mildly reduced or preserved ejection fraction (HFmrEF\/HFpEF). This study aimed to contextualize KCCQ changes in a manner that is relevant to patients and clinicians, thereby improving understanding of this metric in HFmrEF\/HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this prespecified analysis of FINEARTS-HF, a double-blind, randomized, placebo-controlled trial of finerenone in HFmrEF\/HFpEF, we performed exploratory assessments of treatment effects on mean score changes from baseline to 12 months for each of the 23 KCCQ components (scaled from 0 [worst] to 100 [best]) using multivariable linear regression. We further compared the impact of finerenone on the KCCQ-overall summary score (KCCQ-OSS) at 12 months with the expected decline per year. Of 6001 participants in FINEARTS-HF, 5006 completed the KCCQ both at baseline and 12 months (age: 72 \u00b1 10 years, women: 45%, baseline KCCQ-OSS: 63.9 \u00b1 22.0). Finerenone, compared with placebo, numerically improved all but one KCCQ component, with the greatest nominal improvement observed in lower limb oedema frequency (+2.5, 95% CI: 0.9\u20134.1), fatigue burden (+2.2, 95% CI: 0.9\u20133.5), fatigue frequency (+2.1, 95% CI: 0.7\u20133.6), and lower limb oedema burden (+1.8, 95% CI: 0.6\u20132.9). KCCQ-OSS at 12 months was inversely related to age, with finerenone shifting the age-KCCQ-OSS relationship by 4.7 (95% CI: 0.4\u20139.1) years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In FINEARTS-HF, finerenone was associated with modest improvements in health status\u2014most notably lower limb oedema and fatigue\u2014in patients with HFmrEF\/HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag062","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:33:19Z","timestamp":1773145999000},"page":"460-470","source":"Crossref","is-referenced-by-count":1,"title":["Finerenone and quality of life in heart failure: component-level analyses and clinical relevance of the Kansas City cardiomyopathy questionnaire"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3441-7424","authenticated-orcid":false,"given":"Yasuhiro","family":"Hamatani","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 ,","place":["USA"]},{"name":"National Hospital Organization Kyoto Medical Center , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-5865","authenticated-orcid":false,"given":"Alexander","family":"Peikert","sequence":"additional","affiliation":[{"name":"University Heart Center Graz, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-9218","authenticated-orcid":false,"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-0701","authenticated-orcid":false,"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D","family":"Henderson","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca ASST Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4415","authenticated-orcid":false,"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"University of Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer Plc, Research & Development, Pharmaceuticals , Reading ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lage","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer SA , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Bayer AG, Global Medical Affairs , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026091504180814800_xuag062-B1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ejhf.2909","article-title":"Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF and DELIVER trials","volume":"25","author":"Bhatt","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026091504180814800_xuag062-B2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026091504180814800_xuag062-B3","doi-asserted-by":"publisher","first-page":"e001937","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","article-title":"Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026091504180814800_xuag062-B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejheart.2006.10.012","article-title":"Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM","volume":"9","author":"Lewis","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026091504180814800_xuag062-B5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/s1053-2498(01)00298-4","article-title":"Preferences for quality of life or survival expressed by patients with heart failure","volume":"20","author":"Lewis","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"2026091504180814800_xuag062-B6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091504180814800_xuag062-B7","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026091504180814800_xuag062-B8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cardfail.2025.07.008","article-title":"JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure","volume":"31","author":"Kitai","year":"2025","journal-title":"J Card Fail"},{"key":"2026091504180814800_xuag062-B9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091504180814800_xuag062-B10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026091504180814800_xuag062-B11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504180814800_xuag062-B12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504180814800_xuag062-B13","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026091504180814800_xuag062-B14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/jamacardio.2023.1342","article-title":"Association of dapagliflozin vs placebo with individual Kansas City cardiomyopathy questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the DELIVER trial","volume":"8","author":"Peikert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026091504180814800_xuag062-B15","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jchf.2023.04.016","article-title":"Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction","volume":"11","author":"Butt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026091504180814800_xuag062-B16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026091504180814800_xuag062-B17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026091504180814800_xuag062-B18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2026091504180814800_xuag062-B19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026091504180814800_xuag062-B20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/circheartfailure.113.000359","article-title":"Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Joseph","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026091504180814800_xuag062-B21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jchf.2022.03.003","article-title":"Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF","volume":"10","author":"Butler","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026091504180814800_xuag062-B22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/ejhf.2481","article-title":"Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026091504180814800_xuag062-B23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026091504180814800_xuag062-B24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamacardio.2025.0016","article-title":"Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Cunningham","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026091504180814800_xuag062-B25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cardfail.2025.05.006","article-title":"Effects of finerenone on readmissions for heart failure: insights from the FINEARTS-HF trial","volume":"32","author":"Bhatt","year":"2025","journal-title":"J Card Fail"},{"key":"2026091504180814800_xuag062-B26","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1053\/euhj.2002.3255","article-title":"Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population","volume":"23","author":"Hobbs","year":"2002","journal-title":"Eur Heart J"},{"key":"2026091504180814800_xuag062-B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jacc.2024.09.018","article-title":"Time to significant benefit of finerenone in patients with heart failure","volume":"85","author":"Vaduganathan","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026091504180814800_xuag062-B28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/jamacardio.2024.3782","article-title":"Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Vaduganathan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026091504180814800_xuag062-B29","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.jchf.2025.102590","article-title":"Temporal changes in biomarkers, functional status, and quality of life prior to adverse clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"13","author":"Lu","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026091504180814800_xuag062-B30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1161\/CIRCULATIONAHA.124.072158","article-title":"Patient-reported outcomes as end points in heart failure trials","volume":"151","author":"Butler","year":"2025","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag062\/67316451\/xuag062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/460\/67316451\/xuag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/460\/67316451\/xuag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:22:49Z","timestamp":1789460569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/3\/460\/8516375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag062","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}